{"id":"https://openalex.org/W2600387643","doi":null,"title":"sICAM-1 levels in type 2 diabetic atherosclerotic patients","display_name":"sICAM-1 levels in type 2 diabetic atherosclerotic patients","publication_year":2016,"publication_date":"2016-01-01","ids":{"openalex":"https://openalex.org/W2600387643","mag":"2600387643"},"language":"en","primary_location":{"id":"mag:2600387643","doi":null,"is_oa":false,"landing_page_url":"https://www.jocpr.com/articles/sicam1-levels-in-type-2-diabetic-atherosclerotic-patients.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764823877","display_name":"Journal of chemical and pharmaceutical research","issn_l":"0975-7384","issn":["0975-7384"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["norway-1"],"host_organization":"https://openalex.org/P4328139297","host_organization_name":"JOCPR","host_organization_lineage":["https://openalex.org/P4328139297"],"host_organization_lineage_names":["JOCPR"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of chemical and pharmaceutical research","raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017933605","display_name":"Marya Nadim Aldarrouj","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Marya Nadim Aldarrouj","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017602534","display_name":"Faizeh Alqubailey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Faizeh Alqubailey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5028995546","display_name":"Mohammad Ali Nahas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mohammad Ali Nahas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.24991886,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"8","issue":"5","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10831","display_name":"Cell Adhesion Molecules Research","score":0.3215000033378601,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10831","display_name":"Cell Adhesion Molecules Research","score":0.3215000033378601,"subfield":{"id":"https://openalex.org/subfields/2723","display_name":"Immunology and Allergy"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10528","display_name":"Adipokines, Inflammation, and Metabolic Diseases","score":0.3190999925136566,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.23270000517368317,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/soluble-icam-1","display_name":"soluble ICAM-1","score":0.8999999761581421},{"id":"https://openalex.org/keywords/icam-1","display_name":"ICAM-1","score":0.9440000057220459},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9470000267028809},{"id":"https://openalex.org/keywords/atherosclerosis","display_name":"atherosclerosis","score":0.9990000128746033},{"id":"https://openalex.org/keywords/endothelial-dysfunction","display_name":"endothelial dysfunction","score":0.9739999771118164},{"id":"https://openalex.org/keywords/endothelial-activation","display_name":"endothelial activation","score":0.972000002861023},{"id":"https://openalex.org/keywords/cardiovascular-risk-markers","display_name":"cardiovascular risk markers","score":0.6330000162124634},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.9129999876022339},{"id":"https://openalex.org/keywords/body-mass-index","display_name":"body mass index","score":0.9459999799728394},{"id":"https://openalex.org/keywords/lipid-profile","display_name":"lipid profile","score":0.7129999995231628}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7681477069854736},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.757802426815033},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7396092414855957},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.5862464308738708},{"id":"https://openalex.org/C2780972559","wikidata":"https://www.wikidata.org/wiki/Q550061","display_name":"Endothelial dysfunction","level":2,"score":0.5632829666137695},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.5350711345672607},{"id":"https://openalex.org/C2778163477","wikidata":"https://www.wikidata.org/wiki/Q43656","display_name":"Cholesterol","level":2,"score":0.500877857208252},{"id":"https://openalex.org/C2909375385","wikidata":"https://www.wikidata.org/wiki/Q187637","display_name":"Intercellular Adhesion Molecule-1","level":3,"score":0.4694984257221222},{"id":"https://openalex.org/C16224149","wikidata":"https://www.wikidata.org/wiki/Q187637","display_name":"Cell adhesion molecule","level":2,"score":0.4327847957611084},{"id":"https://openalex.org/C185946421","wikidata":"https://www.wikidata.org/wiki/Q3146527","display_name":"ICAM-1","level":3,"score":0.43266865611076355},{"id":"https://openalex.org/C188816634","wikidata":"https://www.wikidata.org/wiki/Q2113324","display_name":"Prospective cohort study","level":2,"score":0.4141538143157959},{"id":"https://openalex.org/C2910068830","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 Diabetes Mellitus","level":3,"score":0.4132084250450134},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3939500153064728},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.18466812372207642},{"id":"https://openalex.org/C2776914184","wikidata":"https://www.wikidata.org/wiki/Q101991","display_name":"Inflammation","level":2,"score":0.13821685314178467}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2600387643","doi":null,"is_oa":false,"landing_page_url":"https://www.jocpr.com/articles/sicam1-levels-in-type-2-diabetic-atherosclerotic-patients.pdf","pdf_url":null,"source":{"id":"https://openalex.org/S2764823877","display_name":"Journal of chemical and pharmaceutical research","issn_l":"0975-7384","issn":["0975-7384"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["norway-1"],"host_organization":"https://openalex.org/P4328139297","host_organization_name":"JOCPR","host_organization_lineage":["https://openalex.org/P4328139297"],"host_organization_lineage_names":["JOCPR"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Journal of chemical and pharmaceutical research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2107366071","https://openalex.org/W2367247299","https://openalex.org/W2125628392","https://openalex.org/W2021366998","https://openalex.org/W2399866006","https://openalex.org/W2350249414","https://openalex.org/W2409443089","https://openalex.org/W2358466212","https://openalex.org/W2363592697","https://openalex.org/W2357509818"],"abstract_inverted_index":{"Atherosclerosis":[0],"is":[1,10,28,56],"the":[2,11,34,162],"main":[3],"cause":[4,13],"of":[5,14,33,47,90,143,192,197,204],"cardiovascular":[6],"disease":[7],"(CVD)":[8],"which":[9,23,61],"major":[12],"morbidity":[15],"and":[16,68,85,101,119,147,151,158,170,181,199],"mortality":[17],"for":[18],"diabetic":[19,75,81,111,116,136,155,159],"patients.":[20],"Endothelial":[21],"dysfunction,":[22],"occurs":[24],"early":[25],"in":[26,52,110,135,154,186],"atherogenesis,":[27],"associated":[29],"with":[30,149],"endothelial":[31,193],"expression":[32],"cell-surface":[35],"adhesion":[36,42],"molecules":[37],"such":[38],"as":[39,189],"ICAM-1":[40,48],"(intercellular":[41],"molecule-1).":[43],"A":[44],"soluble":[45],"form":[46],"can":[49],"be":[50],"measured":[51],"serum.":[53],"Our":[54,174],"study":[55,60],"a":[57,190],"prospective":[58],"cross-sectional":[59],"included":[62],"65":[63],"participants":[64],"aged":[65],"45-72":[66],"years":[67],"divided":[69],"into":[70],"three":[71],"groups:":[72],"type":[73,79,178],"2":[74,80,179],"atherosclerotic":[76,112,156],"patients":[77,83,113,117,137,157,160],"(n=24),":[78],"non-atherosclerotic":[82],"(n=20)":[84],"control":[86,120,140],"group":[87,121],"(n=21).":[88],"Levels":[89,142],"sICAM-1,":[91],"fasting":[92],"blood":[93],"glucose":[94],"(FBG),":[95],"total":[96],"cholesterol":[97],"(TC),":[98],"triglycerides(TG),":[99],"LDL-C":[100],"HDL-C":[102],"were":[103,107,131],"measured.":[104],"sICAM-1":[105,129,144,168,187],"levels":[106,130,169,188,203],"significantly":[108,133,148],"higher":[109,134,202],"compared":[114,138],"to":[115,139],"(P<0.001)":[118,122],"[470.94\u00b115.24":[123],"ng/ml,":[124,126],"336.18\u00b128.32":[125],"273.46\u00b17.2":[127],"respectively].":[128],"also":[132],"group.":[141],"correlated":[145],"positively":[146],"FBG":[150],"BMI":[152],"values":[153],"whereas":[161],"correlation":[163],"was":[164],"not":[165],"significant":[166,184],"between":[167],"lipid":[171],"parameters":[172],"levels.":[173],"results":[175],"showed":[176],"that":[177],"diabetes":[180,198],"atherosclerosis":[182,200],"induce":[183],"increase":[185],"marker":[191],"activation.":[194],"The":[195],"coexistence":[196],"induces":[201],"sICAM-1.":[205]},"counts_by_year":[],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2017-04-07T00:00:00"}